Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POESIA Study: Pleiotropic effects of PCSK9 inhibition and bempedoic acid
2021-005602-10Phase 3Completed
- Sponsor
- Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und Gefäßkrankheiten
- Start
- Nov 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of inclisiran, bempedoic acid and evolocumab in coronary arteriosclerosis and hypercholesterolemia (3 arms), sponsored by Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und Gefäßkrankheiten. Primary endpoint: Co-primary endpoints. Started Nov 2021; status: completed.
02
Drugs
inclisiranbempedoic acidevolocumab
03
Conditions
coronary arteriosclerosishypercholesterolemia
Beyond the preview
Go deeper on 2021-005602-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005602-10.